Multiple Sclerosis News From Medical News Today
Tue, 16 Mar 2010 14:10:20 +0100
Molecule Tells Key Brain Cells To Grow Up, Get To Work, Stanford Study Shows
About four out of every 10 cells in the brain are so-called oligodendrocytes. These cells produce the all-important myelin that coats nerve tracts, ensuring fast, energy-efficient transmission of nerve impulses...
Thu, 11 Mar 2010 04:00:00 PDT
Peptimmune Announces Second Grant Of A United States Patent For PI-2301 Peptide Copolymer For Multiple Sclerosis
Peptimmune, Inc. a privately held biotechnology company, announced the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other autoimmune diseases. The '221 patent claims important treatment modalities for PI-2301 and related compounds...
Tue, 09 Mar 2010 01:00:00 PDT
Researchers Find Further Evidence Linking Epstein-Barr Virus And Risk Of Multiple Sclerosis
Researchers from the Harvard School of Public Health, Walter Reed Army Institute of Research, and a team of collaborators have observed for the first time that the risk of multiple sclerosis (MS) increases by many folds following infection with the Epstein-Barr virus (EBV). This finding implicates EBV as a contributory cause to multiple sclerosis...
Fri, 05 Mar 2010 05:00:00 PDT
Success For Pilot Scheme - Multiple Sclerosis Society
An innovative scheme piloted in Surrey and Sussex, the first of its kind in the country, has had an overwhelmingly positive impact on the lives of people in the area with multiple sclerosis (MS)...
Fri, 05 Mar 2010 03:00:00 PDT
LDN Phase II Trial Results Published - Multiple Sclerosis Society
Results of a phase II clinical trial on the safety and effectiveness of low dose naltrexone (LDN) as a symptom-relief treatment for people with MS have been published in the journal Annals of Neurology. The results of the study suggest that LDN is safe and may have positive effects on the mental quality of life in people with MS; but no effect on a patient's physical quality of life...
Tue, 02 Mar 2010 03:00:00 PDT
Italian Researchers Discover A Possible Onset Mechanism For Multiple Sclerosis
A non-pathogenic bacterium is capable of triggering an autoimmune disease similar to multiple sclerosis in the mouse, the model animal which helps to explain how human diseases work...
Mon, 01 Mar 2010 00:00:00 PDT
Copaxone(R) 15-Year Study In Multiple Sclerosis Patients Demonstrates Robust Long-Term Efficacy And Safety
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced the publication of data from the 15-year clinical study with Copaxone® (glatiramer acetate injection), which is the longest prospective and continuous evaluation ever conducted in relapsing-remitting multiple sclerosis (RRMS) patients. The data were published in the February issue of the journal Multiple Sclerosis...
Sun, 28 Feb 2010 00:00:00 PDT
Exercise Helps Protect Brain Of Multiple Sclerosis Patients
Highly fit multiple sclerosis patients perform significantly better on tests of cognitive function than similar less-fit patients, a new study shows. In addition, MRI scans of the patients showed that the fitter MS patients showed less damage in parts of the brain that show deterioration as a result of MS, as well as a greater volume of vital gray matter...
Fri, 19 Feb 2010 02:00:00 PDT
Migraine More Common In Women With MS
Migraine is seen more frequently in women with multiple sclerosis (MS) than those without, according to a study released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010...
Wed, 17 Feb 2010 02:00:00 PDT
MS Society Launches Major Manifesto Campaign, UK
Today the MS Society launches its 2010 Manifesto in a serious and high profile attempt to encourage the next Government to act upon MS inequalities. The document sets 10 powerful calls for the next Government to act upon...
Tue, 16 Feb 2010 02:00:00 PDT
|
